Updated Jul 11, 7:24 AM · 60 sources analyzed
Key Takeaways
Levomecor terminated both Phase 3 REL-1017 MDD trials simultaneously — a clear program-level failure, not a design fix.
United Therapeutics' ralinepag Phase 3 PAH termination reduces pipeline optionality; Tyvaso remains the company's primary growth driver.
Keros Therapeutics lost its PAH diversification bet with KER-012 termination, refocusing the investment thesis entirely on hematology assets.
📉 Loser
Levomecor Inc. — simultaneous termination of both Phase 3 REL-1017 MDD trials signals a full program collapse with no disclosed path forward
🔭 Watch Next
AstraZeneca's completed AZD2389 Phase 2 in liver fibrosis sets up a potential data disclosure at AASLD or EASL within the next 12 months that could reignite interest in the antifibrotic drug class.
Levomecor's REL-1017 MDD Phase 3 programs both terminated
Levomecor Inc. has terminated two separate Phase 3 trials of REL-1017, an NMDA receptor channel blocker, as adjunctive treatment for major depressive disorder — one a single-arm study (NCT04855747) and one a randomized, double-blind, placebo-controlled trial (NCT06011577). The simultaneous termination of both pivotal-stage programs signals a broad strategic retreat from the MDD indication, not a course correction on a single trial design. For the competitive landscape, it further narrows the field of rapid-acting antidepressants chasing the ketamine-adjacent mechanism, leaving assets like Johnson & Johnson's esketamine and emerging oral NMDA modulators with less near-term competition.
ClinicalTrials.gov ↗Levomecor Inc.
REL-1017 in Major Depressive Disorder (MDD)
Both Phase 3 trials — a multicenter, randomized, double-blind, placebo-controlled study (NCT06011577) and an adjunctive treatment study (NCT04855747) — are now marked TERMINATED on ClinicalTrials.gov. No efficacy or safety data have been released; reasons for termination have not been publicly disclosed.
Why it matters
Terminating two Phase 3 studies simultaneously suggests the decision was not driven by a single trial design flaw — it likely reflects efficacy, safety, or commercial viability concerns significant enough to abandon the entire program. Without a disclosed rationale, investors in adjacent NMDA-targeting platforms should scrutinize whether any shared mechanism liability is implicated.
What to watch
Watch for Levomecor to release any clinical data from the terminated trials at a psychiatry conference such as ACNP or CINP, or via a regulatory disclosure, which would clarify whether failure was efficacy- or safety-driven.
United Therapeutics
Ralinepag in Pulmonary Arterial Hypertension (PAH)
The ADVANCE CAPACITY Phase 3 trial (NCT04084678) — designed to evaluate ralinepag's effect on exercise capacity via peak oxygen consumption (VO2 max) by cardiopulmonary exercise testing — is marked TERMINATED on ClinicalTrials.gov. No efficacy or safety outcome data have been released.
Why it matters
PAH is a well-validated market where mechanism differentiation matters; the termination of a Phase 3 CPET endpoint trial raises questions about whether ralinepag's pharmacology translated to the functional exercise benefit that payers and clinicians demand. United Therapeutics retains a strong commercial base in PAH, so this is a pipeline setback rather than an existential event, but it narrows the growth runway for the prostacyclin franchise.
What to watch
Watch for United Therapeutics to clarify whether ralinepag is permanently shelved or being repositioned to a different endpoint or patient population, likely via investor communications or a pipeline update in the next quarterly earnings call.
Keros Therapeutics
KER-012 in Pulmonary Arterial Hypertension (PAH)
The TROPOS Phase 2 study (NCT05975905) — a double-blind, randomized, placebo-controlled study of KER-012 in combination with background PAH therapy — is now marked TERMINATED on ClinicalTrials.gov. No efficacy or safety data from the study have been disclosed.
Why it matters
Keros built its thesis partly on extending the activin signaling biology beyond hematology into cardiopulmonary disease; a Phase 2 termination without data in PAH compresses that narrative and shifts investor focus entirely to luspatercept-competitive programs in blood disorders. The lack of disclosed rationale for termination is a concern until management addresses it directly.
What to watch
Watch for Keros management to address KER-012's termination and pipeline prioritization at its next investor event or earnings call, and whether the company redirects resources toward its hematology-focused assets.
Sanofi
SAR443579 in Relapsed/Refractory AML, B-ALL, HR-MDS, BPDCN
The first-in-human Phase 1/2 dose-escalation and expansion study of SAR443579 (NCT05086315) — an open-label, multicenter trial in adults and children with relapsed or refractory AML, B-ALL, high-risk MDS, or BPDCN — is marked TERMINATED on ClinicalTrials.gov. No efficacy or safety outcome data have been released.
Why it matters
For Sanofi, this is a pipeline pruning event in a therapeutic area where the bar for differentiation from approved CAR-T and CD3-bispecific platforms is high; losing an early-stage hematology asset is a setback for pipeline diversification but unlikely to move the needle on the overall investment thesis. The termination of a first-in-human study before clear dose-escalation completion is an early and meaningful signal of feasibility problems.
What to watch
Watch for Sanofi to address SAR443579's termination in its next hematology pipeline update, and whether the company discloses whether discontinuation was safety- or activity-driven — timing likely at next quarterly earnings.
Both Phase 3 trials — a multicenter, randomized, double-blind, placebo-controlled study (NCT06011577) and an adjunctive treatment study (NCT04855747) — are now marked TERMINATED on ClinicalTrials.gov. No efficacy or safety data have been released; reasons for termination have not been publicly disclosed.
Why it matters
Dual Phase 3 terminations eliminate REL-1017 as a near-term competitive threat in the NMDA modulator space for MDD, reducing pressure on J&J's esketamine and leaving an opening for oral fast-acting antidepressant programs in development.
Analysis
Terminating two Phase 3 studies simultaneously suggests the decision was not driven by a single trial design flaw — it likely reflects efficacy, safety, or commercial viability concerns significant enough to abandon the entire program. Without a disclosed rationale, investors in adjacent NMDA-targeting platforms should scrutinize whether any shared mechanism liability is implicated.
What to watch
Watch for Levomecor to release any clinical data from the terminated trials at a psychiatry conference such as ACNP or CINP, or via a regulatory disclosure, which would clarify whether failure was efficacy- or safety-driven.
The ADVANCE CAPACITY Phase 3 trial (NCT04084678) — designed to evaluate ralinepag's effect on exercise capacity via peak oxygen consumption (VO2 max) by cardiopulmonary exercise testing — is marked TERMINATED on ClinicalTrials.gov. No efficacy or safety outcome data have been released.
Why it matters
Ralinepag's Phase 3 failure removes a potential oral prostacyclin receptor agonist from the PAH pipeline, consolidating the market position of approved agents like selexipag (Janssen) and inhaled treprostinil (United Therapeutics' own Tyvaso), which competes with the terminated asset's commercial rationale.
Analysis
PAH is a well-validated market where mechanism differentiation matters; the termination of a Phase 3 CPET endpoint trial raises questions about whether ralinepag's pharmacology translated to the functional exercise benefit that payers and clinicians demand. United Therapeutics retains a strong commercial base in PAH, so this is a pipeline setback rather than an existential event, but it narrows the growth runway for the prostacyclin franchise.
What to watch
Watch for United Therapeutics to clarify whether ralinepag is permanently shelved or being repositioned to a different endpoint or patient population, likely via investor communications or a pipeline update in the next quarterly earnings call.
The TROPOS Phase 2 study (NCT05975905) — a double-blind, randomized, placebo-controlled study of KER-012 in combination with background PAH therapy — is now marked TERMINATED on ClinicalTrials.gov. No efficacy or safety data from the study have been disclosed.
Why it matters
KER-012's termination in PAH removes an activin receptor ligand trap (a class of drugs that block signaling molecules involved in vascular remodeling) from an already crowded development field, and raises questions about the depth of Keros's non-hematology pipeline.
Analysis
Keros built its thesis partly on extending the activin signaling biology beyond hematology into cardiopulmonary disease; a Phase 2 termination without data in PAH compresses that narrative and shifts investor focus entirely to luspatercept-competitive programs in blood disorders. The lack of disclosed rationale for termination is a concern until management addresses it directly.
What to watch
Watch for Keros management to address KER-012's termination and pipeline prioritization at its next investor event or earnings call, and whether the company redirects resources toward its hematology-focused assets.
The first-in-human Phase 1/2 dose-escalation and expansion study of SAR443579 (NCT05086315) — an open-label, multicenter trial in adults and children with relapsed or refractory AML, B-ALL, high-risk MDS, or BPDCN — is marked TERMINATED on ClinicalTrials.gov. No efficacy or safety outcome data have been released.
Why it matters
Termination of the first-in-human study of SAR443579 signals that Sanofi is stepping back from this asset in aggressive hematologic malignancies, a space where competition from approved and late-stage cell therapies and bispecific antibodies remains intense.
Analysis
For Sanofi, this is a pipeline pruning event in a therapeutic area where the bar for differentiation from approved CAR-T and CD3-bispecific platforms is high; losing an early-stage hematology asset is a setback for pipeline diversification but unlikely to move the needle on the overall investment thesis. The termination of a first-in-human study before clear dose-escalation completion is an early and meaningful signal of feasibility problems.
What to watch
Watch for Sanofi to address SAR443579's termination in its next hematology pipeline update, and whether the company discloses whether discontinuation was safety- or activity-driven — timing likely at next quarterly earnings.
The Phase 1/2 study evaluating revumenib (a menin inhibitor) in colorectal cancer and other solid tumors (NCT05731947) is now marked TERMINATED on ClinicalTrials.gov. No efficacy or safety data from the solid tumor expansion have been released.
Why it matters
Revumenib's solid tumor program termination narrows its addressable market to the approved AML indication and active hematologic malignancy trials, limiting the commercial ceiling that a broader oncology label would have provided.
Analysis
Revumenib is already approved in relapsed/refractory AML with KMT2A rearrangements or NPM1 mutations, so this termination does not threaten the core commercial story — but it forecloses a potential label expansion into solid tumors that could have substantially expanded peak sales estimates. The menin inhibitor class remains hematology-focused for now, reinforcing the competitive dynamic with competitors like Syndax's rival programs.
What to watch
Watch for Syndax to report updated commercial uptake data for revumenib in AML and any progress in its SNDX-5613 frontline combination studies over the next two quarters.
Takeda terminates TAK-280 first-in-human solid tumor trial
Takeda's Phase 1/2 first-in-human study of TAK-280 in unresectable locally advanced or metastatic solid tumors (NCT05220098) was terminated before dose-escalation was completed, with no efficacy or safety data disclosed.
Why it matters
Early termination of a first-in-human oncology study before dose escalation completion typically signals a prohibitive safety profile, formulation issues, or a strategic portfolio decision — all of which are relevant signals for developers of related oncology assets in this target class.
Analysis
Without a disclosed mechanism of action or reason for termination, this is a cautionary data point for oncology pipelines that depend on early-stage assets advancing through first-in-human studies. Takeda's decision to cut TAK-280 early reflects ongoing pipeline rationalization pressure across large pharma oncology portfolios.
What to watch
Watch for Takeda to address TAK-280's termination in its next oncology pipeline disclosure or R&D day, which would clarify whether this represents a target-class concern or an asset-specific issue.
AstraZeneca completes AZD2389 Phase 2 in liver fibrosis and compensated cirrhosis
AstraZeneca's Phase 2 study of AZD2389 — evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in participants with liver fibrosis and compensated cirrhosis (NCT06750276) — is now marked COMPLETED on ClinicalTrials.gov, with no outcome data yet disclosed.
Why it matters
Liver fibrosis and cirrhosis represent a large unmet need with no approved antifibrotic therapies; completion of a safety and PK/PD Phase 2 study sets the stage for a potential efficacy-focused Phase 2b or Phase 3, and the data readout will be closely watched by developers of competing FXR agonists, NASH-adjacent antifibrotics, and other hepatology assets.
Analysis
AstraZeneca's investment in AZD2389 signals continued commitment to the hepatology space even after high-profile failures in the NASH field broadly; the completion of this study means data could inform whether AZD2389 has sufficient biological activity to justify a larger efficacy study, which would be a meaningful positive signal for the antifibrotic drug class.
What to watch
Watch for AstraZeneca to present AZD2389 Phase 2 safety and biomarker data at a hepatology meeting such as AASLD or EASL, likely within the next 12 months.
Intercept's obeticholic acid pediatric biliary atresia trial terminated
Intercept Pharmaceuticals' Phase 2/3 study of obeticholic acid (OCA) in pediatric patients with biliary atresia post-hepatoportoenterostomy (Kasai procedure) (NCT06121375) was terminated, with no efficacy or safety data released.
Why it matters
Biliary atresia is the leading cause of pediatric liver transplantation and has no approved medical therapy; termination of this OCA study — even without disclosed reasons — leaves a significant therapeutic gap and may signal tolerability or feasibility issues that could inform other FXR agonist developers targeting pediatric liver disease.
Analysis
Given that Intercept's adult NASH program with OCA faced regulatory rejection, termination of this pediatric program reinforces the challenged trajectory for OCA across indications beyond primary biliary cholangitis, where it remains approved. Developers of competing pediatric hepatology assets should watch whether this termination reflects a fundamental OCA safety concern in the pediatric population.
What to watch
Watch for Intercept (now part of Alfasigma) to clarify publicly whether the termination reflects safety signals, enrollment challenges, or a strategic withdrawal, and whether any successor FXR agonist program in pediatric liver disease advances.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
A securities class action lawsuit against Erasca remains active, with a lead plaintiff filing deadline of August 10, 2026, for investors with losses exceeding $100,000. The suit is being publicized by shareholder claims notification services, indicating the litigation is proceeding toward class certification.
PR Newswire ↗